{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T17:20:05Z","timestamp":1792171205444,"version":"4.4.0"},"reference-count":21,"publisher":"American Society of Hematology","issue":"16","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,4,16]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Quadruplet (QUAD) induction and autologous stem cell transplantation (ASCT) leads to high rates of measurable residual disease (MRD) negativity with improved outcomes in multiple myeloma (MM). The t(11;14) confers unique biology and different kinetics of treatment response. We analyzed MRD trajectories of patients treated with QUAD\/ASCT and MRD-adapted post-ASCT management. Of the 302 patients assessed, 47 (16%) had t(11;14)+ MM. Median follow-up was 45.8 months. MRD negativity at &amp;lt;10\u22125 level (MRD &amp;lt;10\u22125) for t(11;14)+ vs t(11;14)\u2212 MM was 9% vs 31%, 36% vs 59%, and 53% vs 75% after induction, after ASCT, and any time on treatment, respectively. The rates of sustained MRD negativity &amp;lt;10\u22125 (S-MRD &amp;lt;10\u22125) were 38% vs 46%. Median time to MRD &amp;lt;10\u22125 was 13.6 vs 7.7 months for t(11;14)+ vs t(11;14)\u2212 MM, respectively. Progression-free survival (PFS) was superior for patients with t(11;14)+ MM, with 4-year PFS rates of 90% vs 72%. In multivariable analysis, S-MRD &amp;lt;10\u22125 were associated with reduced risk of progression or death, with no progression seen in those with t(11;14)+ MM who achieved S-MRD &amp;lt;10\u22125. In the setting of QUAD\/ASCT therapy and MRD-adapted post-ASCT management, t(11;14)+ newly diagnosed MM is associated with improved prognosis despite slow conversion to MRD negativity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2025031952","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T21:20:02Z","timestamp":1769548802000},"page":"1857-1862","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":5,"title":["Distinct trajectory of measurable residual disease in t(11;14) myeloma treated with quadruplet therapy"],"prefix":"10.1182","volume":"147","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8206-8919","authenticated-orcid":false,"given":"Susan","family":"Bal","sequence":"first","affiliation":[{"name":"1Division of Hematology and Oncology, Department of Medicine, The University of Alabama at Birmingham School of Medicine, Birmingham, AL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0467-1819","authenticated-orcid":false,"given":"Gayathri","family":"Ravi","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Oncology, Department of Medicine, The University of Alabama at Birmingham School of Medicine, Birmingham, AL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4377-9742","authenticated-orcid":false,"given":"Binod","family":"Dhakal","sequence":"additional","affiliation":[{"name":"2Division of Hematology\/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6975-1086","authenticated-orcid":false,"given":"Natalie S.","family":"Callander","sequence":"additional","affiliation":[{"name":"3Division of Hematology, Medical Oncology and Palliative Care, Department of Medicine, University of Wisconsin, Madison, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Medvedova","sequence":"additional","affiliation":[{"name":"4Division of Hematology\/Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2371-3655","authenticated-orcid":false,"given":"Bhagirathbhai R.","family":"Dholaria","sequence":"additional","affiliation":[{"name":"5Division of Hematology Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1827-5032","authenticated-orcid":false,"given":"Smith","family":"Giri","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Oncology, Department of Medicine, The University of Alabama at Birmingham School of Medicine, Birmingham, AL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly N.","family":"Godby","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Oncology, Department of Medicine, The University of Alabama at Birmingham School of Medicine, Birmingham, AL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca W.","family":"Silbermann","sequence":"additional","affiliation":[{"name":"2Division of Hematology\/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fady M.","family":"Mikhail","sequence":"additional","affiliation":[{"name":"6Department of Genetics, The University of Alabama at Birmingham School of Medicine, Birmingham, AL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Forest","family":"Huls","sequence":"additional","affiliation":[{"name":"7Department of Pathology, The University of Alabama at Birmingham School of Medicine, Birmingham, AL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5474-3289","authenticated-orcid":false,"given":"Vishnu","family":"Reddy","sequence":"additional","affiliation":[{"name":"7Department of Pathology, The University of Alabama at Birmingham School of Medicine, Birmingham, AL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5362-2469","authenticated-orcid":false,"given":"Luciano J.","family":"Costa","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Oncology, Department of Medicine, The University of Alabama at Birmingham School of Medicine, Birmingham, AL"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"10","key":"2026041611213185800_bib1","doi-asserted-by":"crossref","first-page":"e825","DOI":"10.1016\/S2352-3026(23)00217-X","article-title":"Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial","volume":"10","author":"Voorhees","year":"2023","journal-title":"Lancet Haematol"},{"issue":"4","key":"2026041611213185800_bib2","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"N Engl J Med"},{"issue":"8","key":"2026041611213185800_bib3","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/S1470-2045(24)00282-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial","volume":"25","author":"Moreau","year":"2024","journal-title":"Lancet Oncol"},{"issue":"11","key":"2026041611213185800_bib4","doi-asserted-by":"crossref","first-page":"e890","DOI":"10.1016\/S2352-3026(23)00236-3","article-title":"Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial","volume":"10","author":"Costa","year":"2023","journal-title":"Lancet Haematol"},{"issue":"23","key":"2026041611213185800_bib5","doi-asserted-by":"crossref","first-page":"5988","DOI":"10.1182\/bloodadvances.2020002827","article-title":"A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma","volume":"4","author":"Munshi","year":"2020","journal-title":"Blood Adv"},{"issue":"10","key":"2026041611213185800_bib6","doi-asserted-by":"crossref","first-page":"3735","DOI":"10.1182\/blood.V99.10.3735","article-title":"Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients","volume":"99","author":"Fonseca","year":"2002","journal-title":"Blood"},{"issue":"7","key":"2026041611213185800_bib7","first-page":"2950","article-title":"Multiple myeloma with t(11;14): unique biology and evolving landscape","volume":"12","author":"Bal","year":"2022","journal-title":"Am J Cancer Res"},{"issue":"1","key":"2026041611213185800_bib8","doi-asserted-by":"crossref","first-page":"e113","DOI":"10.1111\/bjh.17627","article-title":"Impact of t(11;14) as a sole and concomitant abnormality on outcomes in multiple myeloma","volume":"195","author":"Bal","year":"2021","journal-title":"Br J Haematol"},{"issue":"12","key":"2026041611213185800_bib9","doi-asserted-by":"crossref","first-page":"5573","DOI":"10.1007\/s00277-024-06026-x","article-title":"T(11;14) with multiple myeloma: standard risk survival but slow and poor response","volume":"103","author":"Liu","year":"2024","journal-title":"Ann Hematol"},{"issue":"5","key":"2026041611213185800_bib10","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1056\/NEJMoa2505133","article-title":"Measurable residual disease-guided therapy in newly diagnosed myeloma","volume":"393","author":"Perrot","year":"2025","journal-title":"N Engl J Med"},{"issue":"suppl 2","key":"2026041611213185800_bib11","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1016\/S2152-2650(24)01887-1","article-title":"OA-46 phase II clinical trial of minimal residual disease response-adapted deferral of transplantation in dysproteinemia (MILESTONE)","volume":"24","author":"Bal","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"8","key":"2026041611213185800_bib12","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"1","key":"2026041611213185800_bib13","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41375-020-01012-4","article-title":"International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials","volume":"35","author":"Costa","year":"2021","journal-title":"Leukemia"},{"issue":"6","key":"2026041611213185800_bib14","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1182\/blood.2024027674","article-title":"Optimal MRD-based end point to support response-adapted treatment cessation in newly diagnosed multiple myeloma","volume":"146","author":"Giri","year":"2025","journal-title":"Blood"},{"issue":"4","key":"2026041611213185800_bib15","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1182\/blood.2024024371","article-title":"EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma","volume":"144","author":"Landgren","year":"2024","journal-title":"Blood"},{"issue":"11","key":"2026041611213185800_bib16","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1200\/JCO-24-02020","article-title":"Minimal residual disease-based end point for accelerated assessment of clinical trials in multiple myeloma: a pooled analysis of individual patient data from multiple randomized trials","volume":"43","author":"Shi","year":"2025","journal-title":"J Clin Oncol"},{"issue":"suppl 16","key":"2026041611213185800_bib17","first-page":"8064-8064","article-title":"Prognostic impact of t(11;14) on PFS1 among patients with myeloma receiving triplet induction therapy","volume":"40","author":"Pirmohammed","year":"2022","journal-title":"J Clin Oncol"},{"issue":"10","key":"2026041611213185800_bib18","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/S1470-2045(20)30452-6","article-title":"Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial","volume":"21","author":"Kumar","year":"2020","journal-title":"Lancet Oncol"},{"issue":"suppl 1","key":"2026041611213185800_bib19","first-page":"338-338","article-title":"Venetoclax in combination with daratumumab and dexamethasone elicits deep, durable responses in patients with t(11;14) relapsed\/refractory multiple myeloma: updated analyses of minimal residual disease negativity in phase 1\/2 study","volume":"142","author":"Bahlis","year":"2023","journal-title":"Blood"},{"key":"2026041611213185800_bib20","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/S2152-2650(25)03464-0","article-title":"Updated interim results of sonrotoclax + dexamethasone in patients with t(11;14)-positive relapsed\/refractory multiple myeloma (R\/R MM): an all-oral treatment","volume":"25","author":"Dhakal","year":"2025","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"2026041611213185800_bib21","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1182\/blood.2024027620","article-title":"Daratumumab-bortezomib-thalidomide-dexamethasone for newly diagnosed myeloma: CASSIOPEIA minimal residual disease results","volume":"146","author":"Corre","year":"2025","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/147\/16\/1857\/2513185\/blood_bld-2025-031952-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/147\/16\/1857\/2513185\/blood_bld-2025-031952-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T15:21:39Z","timestamp":1776352899000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/147\/16\/1857\/566269\/Distinct-trajectory-of-measurable-residual-disease"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,16]]},"references-count":21,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2026,4,16]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2025031952","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4,16]]},"published":{"date-parts":[[2026,4,16]]}}}